Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

November
12
2025

Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence BOCA RATON, Fla. – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive,…

November
06
2025

Treatment for Uncommon Skin Cancer Locations

When most people think of skin cancer, they imagine sun-damaged areas like the face, shoulders, or arms, but there are uncommon skin cancer locations that are often overlooked. Even when the summer is over, skin…

November
06
2025

Shifting the Standard: Why Non-Invasive Skin Cancer Treatments Are the Future of Skin Cancer Therapy

As October is Breast Cancer Awareness Month, a time dedicated to education, early detection, and advancing treatments that prioritize survival and quality of life, we are reminded how non-invasive skin cancer treatment is important in…

November
06
2025

Sensus Healthcare Reports Third Quarter 2025 Financial Results

Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer Revenues of $6.9 million Shipped 16 SRT systems including three to China Fair Deal Agreement (FDA) treatment…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy